Claims

1) Bacterium of the genus *Salmonella* that in its wild type form carries flagella, said bacterium not being capable to induce antibodies against at least one antigenic determinant of flagellin or flagella, for use in a vaccine for the protection of humans or animals against Salmonellosis.

2) Bacterium according to claim 1, wherein said bacterium is not capable to induce antibodies against at least one antigenic determinant of flagellin or flagella due to a mutation in a gene of the flagellar biogenesis pathway.

3) Bacterium according to claim 2, wherein said mutation is located in the flagellin gene.

4) Bacterium according to claims 1-3, wherein said bacterium is selected from the group consisting of *S. typhimurium, enteritidis, choleraesuis, dublin, typhi, abortus-ovi, abortus-equi, paratyphi A and B, derby, hadar, heidelberg, agona* and *arizonae.*

5) Bacterium according to claim 1-4, wherein said bacterium further carries a heterologous gene, said heterologous gene preferably being inserted in the flagellin gene.

6) Bacterium according to claim 1, characterised in that it belongs to a strain of which an example has been deposited with the Centraalbureau voor Schimmelcultures under accession-number CBS 108955.

7) Vaccine for the protection of animals against Salmonellosis, characterised in that the vaccine comprises bacteria as defined in claims 1-6 or antigenic material thereof and a pharmaceutically acceptable carrier.

8) Vaccine according to claim 7, characterised in that said bacteria are in a live attenuated form.

9) Vaccine according to claim 7, characterised in that said bacteria are inactivated.

10) vaccine according to claims 7-9, characterised in that it comprises an adjuvant.

11) vaccine according to claims 7-10, characterised in that it is in a freeze-dried or spray-dried form.

12) Use of a bacterium as defined in claims 1-6 for the manufacture of a vaccine for the protection of humans or animals against infection with a *Salmonella* bacterium or the pathogenic effects of infection.

13) Method for the preparation of a vaccine according to claims 7-11, characterised in that said method comprises the admixing of a bacterium as defined in claims 1-6 or antigenic material thereof and a pharmaceutically acceptable carrier.